Is treatment of fatty liver effective on reducing carotid intima media thickness: A cohort study
Aim: This study was intended to explore the effect of various drugs used to treat fatty liver on intimal-media thickness in patients with NAFLD.
Background: Nonalcoholic fatty liver disease (NAFLD) is an indicator of a broad spectrum of pathologic disorders, which is characterized with macro vesicular steatosis in the absent of alcohol use. It has a wide range of laboratory, clinical and pathological presentations such as simple steatosis to the diseases like non-alcoholic steatohepatitis, fibrosis, and cirrhosis and hepatocellular cancer.
Methods: In this cross - sectional study, as a part of a 10-year cohort study (from 2007-2017) at Tabriz University of Medical Sciences, a group of 100 patients with NAFLD were studied. They were examined by color doppler sonography of the carotid arteries to detect any carotid intima- media thickness, before and one year after treatment with various drugs. The effect of treatment on right and left carotid intima- media thickness (IMT) was examined by using SPSS. V21.
Results: Over all, 36 (36%) patients were male and 64 (64%) were female. The mean age of the patients was a 43.5±10.3 year, ranging from 16 to 64. The decrease in patients' intima- media thickness in both right and left carotids was statistically significant (P<0.0001).
Conclusion: Treatment of patients with nonalcoholic fatty liver has a significant role in reduction of their carotid intima -media thickness and consequently in reducing cerebrovascular events such as stroke.
Keywords: Carotid, Intima Media thickness; Color Doppler Sonography, Fatty Liver.
(Please cite as: Ghaffarifar S, Khoshbaten M, Dordaei F, Zareh Nahandi M, Javad-Rashid R, Shahnazi T. Is treatment of fatty liver effective on reducing carotid intima media thickness; a cohort study. Gastroenterol Hepatol Bed Bench 2018;11(1):9-14).
- Ruhl CE, Everhart JE. (2004). Epidemiology of Nonalcoholic fatty liver. Clin Liver Dis, 8, 501-519.
- Bisceglie AM, Mahachai V, Graham AS. (2003). Advances in the understanding and treatment on nonalcoholic fatty liver disease. Drugs, 63, 2379-2394.
- Yu AS, Keeffe EB. (2002). Nonalcoholic Fatty Liver Disease. Rev Gastroenterol Disord, 2(1), 11–19.
- Neuschwander BA, Caldwell SH. (2003). Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology, 37, 1202-1219.
- Demircioglu F, Kocyigit A, Arslan N, Cakmakci H, Hizli S, Tuncel Sedat A. (2008) Intima-Media Thickness of Carotid Artery and Susceptibility to Atherosclerosis in Obese Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 47, 68–75.
- Brea A, Mosquera D, Martín E, Arizti A, Cordero J.L, Ros E. (2005) Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol, 25, 1045-1050.
- Aygun C, Kocaman O, Sahin T. (2008). Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci, 53, 1352-1357.
- Targher G, Arcaro G. (2007). Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis, 191, 235-240.
- Sanei S, Elahifar MA, Nodehi S, Ansari A. (2011). Sonographic Evaluation of Mean Carotid Intima-media Thickness of patients with Moderate to Severe NonAlcoholic Fatty Liver Disease.ZUMSJ, 42, 35-38.
- Salonen R.M, Nysönen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen T.H, et al. Six-Year Effect of Combined Vitamin C and E Supplementation on Atherosclerotic Progression. The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation, 107, 947-953.
- Crouse J.R, Raichlen J.S, Riley W.A, Evans G.W, Palmer M.A, O’Leary D.H, et al. (2007) Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis. JAMA, 297(12), 1344-1353.
- Mariano M, Gargante P, Galvano F. (2010). L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis- a randomized and controlled clinical trial. Am J Gastroenterol, 105, 1338-1345.
- Katakami N, Yamasaki Y, Hayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa M, et al. (2004) Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia, 47, 1906–1913.